Platform Patents Were Supposed to Protect Gene Editing. Fourteen Years of CRISPR Litigation Say Otherwise.
On March 26, 2026, the Patent Trial and Appeal Board ruled, again, that the Broad Institute invented CRISPR-Cas9 gene editing […]
On March 26, 2026, the Patent Trial and Appeal Board ruled, again, that the Broad Institute invented CRISPR-Cas9 gene editing […]
On May 1, 2026, the company that made OxyContin stopped existing. Purdue Pharma dissolved and its pharmaceutical business restarted as
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
The Short Answer Google Patents is a free document index built for general-purpose prior art search. It has no connection
US Patent 11,530,197 B2 covers the compound that became rentosertib, the TNIK inhibitor that Insilico Medicine says is the first
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
The FDA Orange Book does not link to the USPTO’s patent database. The USPTO’s patent database does not link to
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
Eliquis has four expiration dates. Not one, not two. Four. The composition-of-matter patent covering apixaban was originally set to expire
A comprehensive freedom-to-operate analysis for a pharmaceutical asset takes four to twelve weeks and costs $50,000 to $200,000 in legal
On September 9, 2026, Bristol-Myers Squibb’s five-year new chemical entity (NCE) exclusivity for Sotyktu (deucravacitinib) reaches its four-year mark. That
On October 8, 2025, the U.S. Patent and Trademark Office quietly admitted something the patent search industry had been saying
Stop Searching Patents. Start Asking Them Questions. Read Post »
Sign in or create a free account to read this DrugPatentWatch article